Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Abbott India: DPCO blues - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jul 22, 2003

    Abbott India: DPCO blues

    Following the worldwide sale of BASF AG’s (Knoll’s parent company) pharmaceutical business to Abbot Laboratories in Dec ’00, Knoll Pharma had become a subsidiary of BASF AG. Consequently, Knoll Pharma was renamed as Abbott India Ltd (AIL) with effect from July ’02. Abbot Laboratories is a global healthcare company devoted to discovery, development, manufacture and marketing of pharmaceuticals, nutritional and medical products including devices and diagnostics. The merger is expected to increase the company’s market share and open up new opportunities for higher growth and greater profitability. In this context, let us briefly understand the business of AIL.

    AIL is the leading player in the domestic insulin, anti-diabetic, pain control and antacid markets. The company’s major brands are Digene, Clivarine, Aciguard, Epilex, Brufen and Bruzen MR. AIL operates in both acute and lifestyle therapies. In the acute segments like gastroenterology and pain management, the company has witnessed volume pressure. However, in the lifestyle segments of diabetes, Central Nervous System (CNS) and Urology, AIL has registered strong growth. New product introduction has also been one of the key growth drivers for the company. During the year ended Nov’02, AIL launched Ganaton (gastro motility disorders), Celax range of once a day formulations, a premium anti-biotic for respiratory tract infections and Hytrin-used in the treatment of Benign Prostatic Hyperplasia (BPH). AIL has also commenced the marketing of various products imported from its parent.

    Financial overview
      Dec-00 Nov-01* Nov-02
    Revenues (Rs m) 3,156.0 3,370.9 3,399.0
    Growth in revenues - 6.8% 0.8%
    PAT (Rs m) 715.0 534.5 558.0
    Growth in PAT - -25.2% 4.4%
    OPM (%) 15.0 17.0 22.3
    NPM (%) 22.7 15.9 16.4
    * Annualised

    On the financial front, over the past few years, APL has witnessed modest growth due to intense competition, low priced generics and proliferation of spurious products. For the year ended Nov ’02, although AIL had recorded only a marginal increase in revenues, bottomline registered a 4% rise. This was primarily due to the fact that that the benefits of the extensive restructuring exercise undertaken by the company have started to accrue. In Nov-02, AIL disposed off its Jejuri undertaking. The plant had ceased to enjoy tax benefits and had also seen a drop in the capacity utilization on account of a decline in the volumes of Brufen and Digene. Such measures are likely to further improve the operating margins of the company going forward.

    Absence of product patents has resulted in AIL showing reluctance in aggressively launching new products from its parents portfolio. This has stunted the growth of the company to some extent. Moreover, a major portion of the company’s products is under DPCO cover. Rigorous price controls employed by the government have further affected the growth prospects of the company. Recently, National Pharmaceuticals Pricing Authority (NPPA) reduced the prices of three products. This is likely to affect the performance of the company in the near term.

    NPPA effect
    Formulation/Composition Name Pack Size Existing Price (Rs.) Revised Price (Rs.) Change (%)
    Erykid-125 DIS Tablet 10's Blister 18.0 15.1 (16.3)
    Erythromycin Ethyl Succinate Tablet 6's Al_St 45.3 35.8 (21.1)
    Erythromycin Ethyl Succinate Tablet 6's Al_Bl 45.0 35.5 (21.2)

    However, with India being a signatory of WTO resolution on TRIPS, product patents will be introduced in 2005. The protection provided to patented products will encourage MNCs like AIL to make more aggressive launch from its parent’s product portfolio and thus improve the performance of the company in the long term.

    Comparative Valuation
      Abbot (India) Aventis Pfizer GSK Pharma
    Current Price (Rs) 284 358 411 365
    EPS (Rs) 34.5 26.5 26.4 17.2
    P/E (x) 8.2 13.5 15.6 21.2
    OPM (%) 15.0 15.8 11.7 16.7
    M Cap/Sales (x) 0.7 1.3 1.8 2.5
    *All valuations pertain latest declared annual results

    AIL is currently trading at a P/E of 6.7x its 1HFY04 earnings. The company has a low Market cap / Sales ratio as compared to its peers implying relatively weaker brand equity. Moreover, a high DPCO cover and competition led drop in human insulins prices could affect the performance of the company in the near term. However, for the long term, post 2005, with the introduction of product patents, aggressive product launches from parent’s product portfolio and dilution of DPCO cover could help the company improve its performance.



    Equitymaster requests your view! Post a comment on "Abbott India: DPCO blues ". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 16, 2017 (Close)


    • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts